Scientists test new drug combo to make risky cancer transplants safer
NCT ID NCT02996773
Summary
This study tested the safety of swapping out one drug (cyclophosphamide) for another (bendamustine) in the days following a bone marrow transplant. It involved 50 patients with various blood cancers who needed a transplant but lacked a perfectly matched donor. The goal was to see if the new drug combination could reduce serious side effects like graft-versus-host disease while still allowing the transplant to work.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
Conditions
Explore the condition pages connected to this study.